OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Clinical trial design in the era of precision medicine
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Showing 1-25 of 160 citing articles:
Transformative Potential of AI in Healthcare: Definitions, Applications, and Navigating the Ethical Landscape and Public Perspectives
Molly Bekbolatova, Jonathan Mayer, Chi Wei Ong, et al.
Healthcare (2024) Vol. 12, Iss. 2, pp. 125-125
Open Access | Times Cited: 128
Molly Bekbolatova, Jonathan Mayer, Chi Wei Ong, et al.
Healthcare (2024) Vol. 12, Iss. 2, pp. 125-125
Open Access | Times Cited: 128
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare
Lara Marques, Bárbara Costa, Mariana Pereira, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 332-332
Open Access | Times Cited: 80
Lara Marques, Bárbara Costa, Mariana Pereira, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 332-332
Open Access | Times Cited: 80
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
Liuying Wang, Yongzhen Song, Hesong Wang, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 253-253
Open Access | Times Cited: 52
Liuying Wang, Yongzhen Song, Hesong Wang, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 253-253
Open Access | Times Cited: 52
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 51
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 51
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 48
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 48
Natural products for combating multidrug resistance in cancer
Ting Chen, Zhicheng Xiao, Xiaoyan Liu, et al.
Pharmacological Research (2024) Vol. 202, pp. 107099-107099
Open Access | Times Cited: 30
Ting Chen, Zhicheng Xiao, Xiaoyan Liu, et al.
Pharmacological Research (2024) Vol. 202, pp. 107099-107099
Open Access | Times Cited: 30
The evolving landscape of tissue‐agnostic therapies in precision oncology
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 22
Vivek Subbiah, Mohamed A. Gouda, Bettina Ryll, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 5, pp. 433-452
Open Access | Times Cited: 22
Novel clinical trial designs emerging from the molecular reclassification of cancer
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 3
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 3
Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges
Prafulla Tiwari, Rishi Pal, Manju J. Chaudhary, et al.
Drug Development Research (2023) Vol. 84, Iss. 8, pp. 1652-1663
Closed Access | Times Cited: 41
Prafulla Tiwari, Rishi Pal, Manju J. Chaudhary, et al.
Drug Development Research (2023) Vol. 84, Iss. 8, pp. 1652-1663
Closed Access | Times Cited: 41
Precision Oncology: Evolving Clinical Trials across Tumor Types
I-Wen Song, Henry Hiep Vo, Ying‐Shiuan Chen, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1967-1967
Open Access | Times Cited: 38
I-Wen Song, Henry Hiep Vo, Ying‐Shiuan Chen, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1967-1967
Open Access | Times Cited: 38
Artificial Intelligence in Drug Discovery and Development
Kit‐Kay Mak, Yi-Hang Wong, Mallikarjuna Rao Pichika
Springer eBooks (2023), pp. 1-38
Closed Access | Times Cited: 35
Kit‐Kay Mak, Yi-Hang Wong, Mallikarjuna Rao Pichika
Springer eBooks (2023), pp. 1-38
Closed Access | Times Cited: 35
BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Liwei Zhao, Peng Liu, Misha Mao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2448-2469
Open Access | Times Cited: 33
Liwei Zhao, Peng Liu, Misha Mao, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2448-2469
Open Access | Times Cited: 33
Blood protein levels predict leading incident diseases and mortality in UK Biobank
Danni A. Gadd, Robert F. Hillary, Zhana Kuncheva, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 27
Danni A. Gadd, Robert F. Hillary, Zhana Kuncheva, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 27
Hot topics in allergen immunotherapy, 2023: Current status and future perspective
Magdalena Zemelka‐Wiącek, Ioana Agache, Cezmi A. Akdiş, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 823-842
Open Access | Times Cited: 27
Magdalena Zemelka‐Wiącek, Ioana Agache, Cezmi A. Akdiş, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 823-842
Open Access | Times Cited: 27
Cancer Evolution: A Multifaceted Affair
Giovanni Ciriello, Luca Magnani, Sarah J. Aitken, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 36-48
Open Access | Times Cited: 27
Giovanni Ciriello, Luca Magnani, Sarah J. Aitken, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 36-48
Open Access | Times Cited: 27
Precision cancer medicine: Concepts, current practice, and future developments
Anders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 455-481
Open Access | Times Cited: 25
Anders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 455-481
Open Access | Times Cited: 25
A review on advancements in the application of starch-based nanomaterials in biomedicine: Precision drug delivery and cancer therapy
Jinjin Pei, Yuqiang Yan, Selvaraj Jayaraman, et al.
International Journal of Biological Macromolecules (2024) Vol. 265, pp. 130746-130746
Closed Access | Times Cited: 15
Jinjin Pei, Yuqiang Yan, Selvaraj Jayaraman, et al.
International Journal of Biological Macromolecules (2024) Vol. 265, pp. 130746-130746
Closed Access | Times Cited: 15
Anticancer drugs: How to select small molecule combinations?
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 14
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 14
Transforming Clinical Research: The Power of High-Throughput Omics Integration
Rui Vitorino
Proteomes (2024) Vol. 12, Iss. 3, pp. 25-25
Open Access | Times Cited: 14
Rui Vitorino
Proteomes (2024) Vol. 12, Iss. 3, pp. 25-25
Open Access | Times Cited: 14
Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials
Ranil Vikraman Kumarasamy, Prabhu Manickam Natarajan, Vidhya Rekha Umapathy, et al.
Frontiers in Nanotechnology (2024) Vol. 6
Open Access | Times Cited: 14
Ranil Vikraman Kumarasamy, Prabhu Manickam Natarajan, Vidhya Rekha Umapathy, et al.
Frontiers in Nanotechnology (2024) Vol. 6
Open Access | Times Cited: 14
Artificial Intelligence in Drug Discovery and Development
Kit‐Kay Mak, Yi-Hang Wong, Mallikarjuna Rao Pichika
Springer eBooks (2024), pp. 1461-1498
Closed Access | Times Cited: 13
Kit‐Kay Mak, Yi-Hang Wong, Mallikarjuna Rao Pichika
Springer eBooks (2024), pp. 1461-1498
Closed Access | Times Cited: 13
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 10
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 10
My battle with cancer. Part 1
Mikhail V. Blagosklonny
Oncoscience (2024) Vol. 11, pp. 1-14
Open Access | Times Cited: 9
Mikhail V. Blagosklonny
Oncoscience (2024) Vol. 11, pp. 1-14
Open Access | Times Cited: 9
Omics-based molecular classifications empowering in precision oncology
Zhaokai Zhou, Ting Lin, Shuang Chen, et al.
Cellular Oncology (2024) Vol. 47, Iss. 3, pp. 759-777
Closed Access | Times Cited: 9
Zhaokai Zhou, Ting Lin, Shuang Chen, et al.
Cellular Oncology (2024) Vol. 47, Iss. 3, pp. 759-777
Closed Access | Times Cited: 9
Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position
Ivica Smokovski, Nanette Steinle, Andrew Behnke, et al.
The EPMA Journal (2024) Vol. 15, Iss. 2, pp. 149-162
Open Access | Times Cited: 9
Ivica Smokovski, Nanette Steinle, Andrew Behnke, et al.
The EPMA Journal (2024) Vol. 15, Iss. 2, pp. 149-162
Open Access | Times Cited: 9
